Compare MSLE & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MSLE | PFO |
|---|---|---|
| Founded | N/A | 1991 |
| Country | Canada | United States |
| Employees | 17 | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 118.6M |
| IPO Year | N/A | N/A |
| Metric | MSLE | PFO |
|---|---|---|
| Price | $6.71 | $9.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.4K | ★ 38.6K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $8.01 |
| 52 Week High | $13.39 | $9.90 |
| Indicator | MSLE | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 47.22 |
| Support Level | $6.73 | $8.85 |
| Resistance Level | $8.59 | $9.76 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 22.22 | 51.44 |
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.